G Hortobagyi

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Toward individualized breast cancer therapy: translating biological concepts to the bedside
    Gabriel N Hortobagyi
    Breast Cancer Research Program, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, P O Box 301439, Houston, Texas 77230 1439, USA
    Oncologist 17:577-84. 2012
  2. pmc Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Proteomics 8:11. 2011
  3. pmc Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
    Mario Giuliano
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Breast Cancer Res 13:R67. 2011
  4. pmc Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells
    Quanri Jin
    Department of Breast Medical Oncology, The University of Texas M, d, Anderson Cancer Center, Houston, TX 77030, USA
    Breast Cancer Res 12:R96. 2010
  5. pmc Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells
    Satoshi Nakayama
    Central Research Laboratories, Sysmex Corporation, 4 4 4, Takatsukadai, Nishi ku, Kobe, Japan
    Breast Cancer Res 11:R12. 2009
  6. pmc CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer Res 9:R87. 2007
  7. pmc Effect of training-sample size and classification difficulty on the accuracy of genomic predictors
    Vlad Popovici
    Bioinformatics Core Facility, Swiss Institute of Bioinformatics, Genopode Building, Quartier Sorge, Lausanne CH 1015, Switzerland
    Breast Cancer Res 12:R5. 2010
  8. pmc PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, University of Texas M, d, Anderson Cancer Center, Houston, TX, USA
    Breast Cancer Res 10:R27. 2008
  9. pmc Fingerprinting lymph node metastases
    W Fraser Symmans
    Ann Surg Oncol 15:1275-6. 2008
  10. doi request reprint A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer
    Gabriel N Hortobagyi
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, TX 77030 4009, USA
    Cancer 116:1440-5. 2010

Research Grants

  1. UTMDACC SPORE in Breast Cancer
    Gabriel Hortobagyi; Fiscal Year: 2007
  2. UTMDACC SPORE in Breast Cancer
    Gabriel Hortobagyi; Fiscal Year: 2007

Detail Information

Publications150 found, 100 shown here

  1. pmc Toward individualized breast cancer therapy: translating biological concepts to the bedside
    Gabriel N Hortobagyi
    Breast Cancer Research Program, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, P O Box 301439, Houston, Texas 77230 1439, USA
    Oncologist 17:577-84. 2012
    ..As we move forward with increasing molecular segmentation of breast cancer and develop new, highly targeted agents, molecular diagnostics must accompany molecular therapeutics to implement the concept of personalized cancer therapy...
  2. pmc Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Proteomics 8:11. 2011
    ..abstract:..
  3. pmc Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
    Mario Giuliano
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Breast Cancer Res 13:R67. 2011
    ..We assessed the prognostic impact of CTCs according to different first-line systemic treatments, and explored their potential predictive value in MBC patients...
  4. pmc Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells
    Quanri Jin
    Department of Breast Medical Oncology, The University of Texas M, d, Anderson Cancer Center, Houston, TX 77030, USA
    Breast Cancer Res 12:R96. 2010
    ..We hypothesized that FASN is directly phosphorylated by HER2, resulting in enhanced signaling and tumor progression in breast cancer cells...
  5. pmc Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells
    Satoshi Nakayama
    Central Research Laboratories, Sysmex Corporation, 4 4 4, Takatsukadai, Nishi ku, Kobe, Japan
    Breast Cancer Res 11:R12. 2009
    ..We hypothesized that cyclin-dependent kinase (CDK) 1 activity and CDK2 activity in cancer cells, which reflect the activation state of the spindle assembly checkpoint and the growth state, respectively, predict sensitivity to paclitaxel...
  6. pmc CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer Res 9:R87. 2007
    ..We performed gene expression analysis to identify molecular predictors of resistance to preoperative concomitant trastuzumab and paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (T/FEC)...
  7. pmc Effect of training-sample size and classification difficulty on the accuracy of genomic predictors
    Vlad Popovici
    Bioinformatics Core Facility, Swiss Institute of Bioinformatics, Genopode Building, Quartier Sorge, Lausanne CH 1015, Switzerland
    Breast Cancer Res 12:R5. 2010
    ....
  8. pmc PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, University of Texas M, d, Anderson Cancer Center, Houston, TX, USA
    Breast Cancer Res 10:R27. 2008
    ..In vitro evidence suggests that PIK3CA (phosphatidylinositol 3-kinase, catalytic, alpha polypeptide) activation may be associated with altered chemotherapy sensitivity in cancer...
  9. pmc Fingerprinting lymph node metastases
    W Fraser Symmans
    Ann Surg Oncol 15:1275-6. 2008
  10. doi request reprint A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer
    Gabriel N Hortobagyi
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, TX 77030 4009, USA
    Cancer 116:1440-5. 2010
    ..Orally administered UFT and leucovorin provided higher peak plasma concentrations of 5-FU and prolonged therapeutic 5-FU concentrations compared with continuous infusion of 5-FU...
  11. doi request reprint A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer
    Gabriel N Hortobagyi
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 116:2301-6. 2010
    ..Orally administered UFT and leucovorin provide higher peak plasma concentrations of 5-FU and prolonged therapeutic 5-FU concentrations compared with continuous infusion of 5-FU...
  12. ncbi request reprint Two good choices to prevent breast cancer: great taste, less filling
    Gabriel N Hortobagyi
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Cancer Prev Res (Phila) 3:681-5. 2010
    ..For 12 years, the public has avoided Food and Drug Administration-approved tamoxifen or raloxifene for breast cancer risk reduction; it is time to reemphasize the great preventive benefit of these agents to the public...
  13. ncbi request reprint Future directions in the endocrine therapy of breast cancer
    Gabriel N Hortobagyi
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Breast Cancer Res Treat 80:S37-9. 2003
    ....
  14. ncbi request reprint The global breast cancer burden: variations in epidemiology and survival
    Gabriel N Hortobagyi
    The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Clin Breast Cancer 6:391-401. 2005
    ..This will aid the development of tailored strategies to improve outcomes in general as well as the standard of care for underserved populations and reduce the burden of breast cancer worldwide...
  15. ncbi request reprint Moving into the future: treatment of bone metastases and beyond
    Gabriel N Hortobagyi
    Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, 77030, USA
    Cancer Treat Rev 31:9-18. 2005
    ..The current evidence of the potential of zoledronic acid in addressing CTIBL and preventing bone metastases is reviewed...
  16. ncbi request reprint New approaches to breast cancer therapy
    Gabriel N Hortobagyi
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Breast Cancer Res Treat 80:S1-2; discussion S13-8. 2003
    ..In this way, the therapeutic options can be refined and adapted to the ultimate benefit of all women with breast cancer...
  17. ncbi request reprint The status of breast cancer management: challenges and opportunities
    Gabriel N Hortobagyi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center Houston, 77030 4009, USA
    Breast Cancer Res Treat 75:S61-5; discussion S57-9. 2002
    ....
  18. ncbi request reprint Integration of docetaxel into adjuvant breast cancer treatment regimens
    Gabriel N Hortobagyi
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030 4009, USA
    Oncology (Williston Park) 16:27-33. 2002
    ....
  19. ncbi request reprint Adjuvant therapy for breast cancer
    G Hortobagyi
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Annu Rev Med 51:377-92. 2000
    ..In this report, we review the state of adjuvant therapy for breast cancer...
  20. ncbi request reprint Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:4691-9. 2004
    ..To evaluate the efficacy of radiation in patients treated with neoadjuvant chemotherapy and mastectomy...
  21. pmc Evaluation of biological pathways involved in chemotherapy response in breast cancer
    Attila Tordai
    Department of Breast Medical Oncology, The University of Texas M, d, Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Breast Cancer Res 10:R37. 2008
    ..Our goal was to examine the association between biological pathways and response to chemotherapy in estrogen receptor-positive (ER+) and ER-negative (ER-) breast tumors separately...
  22. ncbi request reprint Breast cancer molecular subtypes respond differently to preoperative chemotherapy
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 11:5678-85. 2005
    ..The goal of this research was to determine if these different molecular subtypes of breast cancer also respond differently to preoperative chemotherapy...
  23. ncbi request reprint Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence
    L Johnetta Blakely
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:465-9. 2004
    ..The goal of the current study was to assess the effect of pregnancy on the subsequent risk of recurrence after treatment for breast carcinoma, adjusting for established prognostic factors...
  24. ncbi request reprint Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease
    Edgardo Rivera
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Breast J 8:2-9. 2002
    ..The benefit was greater on patients with node-negative primary tumors. In patients with stage IV-NED disease, doxorubicin-based chemotherapy should be considered standard treatment after adequate local control is achieved...
  25. doi request reprint Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 27:220-6. 2009
    ..The goal of this study was to describe the effect of race on pathologic complete response (pCR) rates and survival outcomes in women with triple receptor-negative (TN) breast cancers...
  26. ncbi request reprint Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 23:8331-9. 2005
    ..To combine clinical variables associated with pathologic complete response (pCR) and distant metastasis-free survival (DMFS) after preoperative chemotherapy (PC) into a prediction nomogram...
  27. ncbi request reprint Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:1022-7. 2008
    ..For patients with Stage II breast cancer with one to three positive lymph nodes, controversy exists about whether radiation as a component of treatment provides a survival benefit...
  28. pmc Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer
    Abigail S Caudle
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 28:1821-8. 2010
    ..Because many of these variables are also associated with response to NCT, novel molecular predictors are needed to identify patients at risk for progression on standard NCT...
  29. ncbi request reprint Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt
    Fumiyuki Yamasaki
    Breast Cancer Translational Research Laboratory, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Res 67:5779-88. 2007
    ..We propose that acquired erlotinib resistance associated with MMAC1/PTEN down-regulation and Akt activation could be overcome by inhibitors of signaling through the phosphatidylinositol 3-kinase pathway...
  30. doi request reprint Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:1275-81. 2008
    ..In this study, we compared response to neoadjuvant chemotherapy and survival between patients with TNBC and non-TNBC...
  31. ncbi request reprint Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation
    Wendy A Woodward
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 57:336-44. 2003
    ....
  32. ncbi request reprint Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes
    Gabriel N Hortobagyi
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1354, Houston, TX 77030 4009, USA
    Breast Cancer Res Treat 122:409-18. 2010
    ..The observed differences in survival favored the combination arm. A clinical benefit was also seen in patients in the KPS 70-80 subgroup...
  33. ncbi request reprint Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, BO Box 301439, Houston, TX 77030 1439, USA
    Breast Cancer Res Treat 121:301-9. 2010
    ..Cell line-derived predictors of response to four commonly used chemotherapy drugs did not predict response accurately in patients...
  34. ncbi request reprint Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
    Valentina Guarneri
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:1037-44. 2006
    ..To evaluate whether hormonal receptor (HR) status can influence the prognostic significance of pathologic complete response (pCR)...
  35. ncbi request reprint Proapoptotic and antitumor activities of adenovirus-mediated p202 gene transfer
    Yi Ding
    Departments of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:3290-7. 2002
    ..We examined the effects of Ad-p202 infection on human breast cancer cells. Furthermore, we tested the efficacy of Ad-p202 treatment on breast and pancreatic cancer xenograft models...
  36. ncbi request reprint Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 62:351-7. 2005
    ..To identify the clinical and pathologic factors predictive of locoregional recurrence (LRR) after neoadjuvant chemotherapy, mastectomy, and radiotherapy...
  37. ncbi request reprint Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response
    Radhika Rajan
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 100:1365-73. 2004
    ..In the current study, the authors investigated the contribution of assessing tumor cellularity in the pathologic evaluation of response to chemotherapy...
  38. ncbi request reprint Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1195-200. 2007
    ..The purpose of this study was to review the efficacy and safety of a similar regimen outside the setting of a clinical trial...
  39. doi request reprint Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage
    Ricardo H Alvarez
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer 116:1210-7. 2010
    ....
  40. ncbi request reprint The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study
    Alberto J Montero
    Division of Cancer Medicine, Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:229-35. 2005
    ..The purpose of the current study, performed retrospectively, was to characterize the natural history of this subset of patients, both before and after the advent of adjuvant anthracycline-based chemotherapy and tamoxifen...
  41. pmc Locoregional treatment outcomes after multimodality management of inflammatory breast cancer
    Ian J Bristol
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 72:474-84. 2008
    ....
  42. doi request reprint Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers
    Giampaolo Bianchini
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 28:4316-23. 2010
    ....
  43. ncbi request reprint Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer
    Edgardo Rivera
    Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:987-93. 2002
    ..The primary objective of this study was to estimate the objective tumor response rate of orally administered eniluracil and 5-FU in the treatment of anthracycline- and taxane-resistant advanced breast cancer...
  44. ncbi request reprint Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma
    Edgardo Rivera
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 94:2321-6. 2002
    ....
  45. pmc Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 102:8315-20. 2005
    ..Low tau expression may be used as a marker to select patients for paclitaxel therapy. Inhibition of tau function might be exploited as a therapeutic strategy to increase sensitivity to paclitaxel...
  46. ncbi request reprint Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:4236-44. 2006
    ..We developed a multigene predictor of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil-doxorubicin-cyclophosphamide (T/FAC) chemotherapy and assessed its predictive accuracy on independent cases...
  47. pmc Genomic grade index is associated with response to chemotherapy in patients with breast cancer
    Cornelia Liedtke
    DPhil, Departments of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 27:3185-91. 2009
    ....
  48. ncbi request reprint Global gene expression changes during neoadjuvant chemotherapy for human breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 8:461-8. 2002
    ..The purpose of this study was to analyze global gene expression changes in serial tumor core biopsy specimens taken during neoadjuvant chemotherapy for primary breast cancer...
  49. ncbi request reprint Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy
    Chafika Mazouni
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer 109:496-501. 2007
    ....
  50. pmc Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer
    Dongwei Zhang
    Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:6639-48. 2009
    ..Epidermal growth factor receptor (EGFR) expression is an independent poor prognostic factor in IBC. The purpose of this study was to determine the effect on IBC tumorigenicity and metastasis of blocking the EGFR pathway...
  51. ncbi request reprint DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design
    Fabrice Andre
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, United States
    Biochim Biophys Acta 1766:197-204. 2006
    ..Next, we will compare advantages and limitations of cohort-based and case-control studies. The choice of end-point to discriminate between sensitive and resistant patients will also be examined...
  52. ncbi request reprint T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy
    Amit K Garg
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 59:138-45. 2004
    ..To help define the clinical and pathologic predictors of locoregional recurrence (LRR) in breast cancer patients treated with neoadjuvant chemotherapy and mastectomy without radiotherapy for early-stage disease...
  53. ncbi request reprint Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer
    Mary C Pinder
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:3808-15. 2007
    ..Limited data are available on long-term cardiac safety of adjuvant anthracycline chemotherapy in breast cancer patients over age 65 years. We evaluated rates and predictors of congestive heart failure (CHF) in this population...
  54. ncbi request reprint Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1459-66. 2006
    ..The aim of the current study was to develop and validate nomograms for predicting residual tumor size and probability of a patient becoming eligible for breast conservation surgery after NACT...
  55. ncbi request reprint Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience
    Valentina Guarneri
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:4107-15. 2006
    ..D. Anderson Cancer Center (Houston, TX)...
  56. ncbi request reprint Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 66:352-7. 2006
    ..The purpose of this study was to compare the rates of LRR as a function of prognostic index score for patients treated with BCT or mastectomy plus radiation after neoadjuvant chemotherapy...
  57. ncbi request reprint Efficacy of anastrozole in male breast cancer
    Sharon H Giordano
    University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Clin Oncol 25:235-7. 2002
    ..D. Anderson from 1990 to 1999 were reviewed. Five male patients with metastatic breast cancer who were treated at M. D. Anderson with anastrozole were identified. We now report on these five cases...
  58. ncbi request reprint Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors
    Emer O Hanrahan
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas
    Cancer 104:1158-71. 2005
    ..An analysis of prognostic factors for these patients also is presented...
  59. ncbi request reprint Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy
    Wendy A Woodward
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 57:327-35. 2003
    ..To assess the incidence of long-term toxicity after postmastectomy radiation and doxorubicin-based adjuvant chemotherapy...
  60. ncbi request reprint A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer
    Jonathan C Trent
    Departments of Sarcoma Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:2426-34. 2003
    ..For Phase II, the purpose was to determine the safety and efficacy of this combination as first-line treatment in patients with metastatic breast cancer (MBC)...
  61. pmc Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes
    Elizabeth A Mittendorf
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:7381-8. 2009
    ..To evaluate HER2 status in residual tumor identified at the time of surgery in patients not achieving a pathologic complete response (pCR) and to determine the effect of alterations in HER2 status on recurrence-free survival (RFS)...
  62. ncbi request reprint Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients
    Tse Kuan Yu
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 96:1676-81. 2004
    ..To obtain additional information about this association, we investigated the association between paclitaxel chemotherapy and radiation pneumonitis in patients participating in a phase III randomized study...
  63. ncbi request reprint Development of candidate genomic markers to select breast cancer patients for dasatinib therapy
    Stacy Moulder
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 9:1120-7. 2010
    ..We defined three conceptually different potential predictors of dasatinib response that were reproducible across cell lines and human data. These candidate markers are being tested in a clinical trial to determine their utility...
  64. doi request reprint Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer
    Jeffrey M Albert
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 77:1296-302. 2010
    ....
  65. ncbi request reprint Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma
    Fan Zhang
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1758-65. 2003
    ..The objective of this study was to determine whether HER-2 overexpression is associated with improved response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) in patients with breast carcinoma...
  66. ncbi request reprint PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
    Yoichi Nagata
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 6:117-27. 2004
    ..Thus, PTEN deficiency is a powerful predictor for trastuzumab resistance. Additionally, PI3K inhibitors rescued PTEN loss-induced trastuzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance...
  67. ncbi request reprint AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model
    I Fen Chen
    Department of Molecular and Cellular Oncology, Unit 108, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, 77030, USA
    Mol Cancer Ther 5:1-7. 2006
    ..Together, these results suggest that AIM2 associates with tumor suppression activity and may serve as a potential therapeutic gene for future development of AIM2-based gene therapy for human breast cancer...
  68. doi request reprint PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase
    Chandra Bartholomeusz
    Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:1802-11. 2010
    ..To determine the role of PEA-15 in breast cancer...
  69. ncbi request reprint Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma
    Edgardo Rivera
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1348-54. 2006
    ..A single-institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer...
  70. ncbi request reprint Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer
    Bita Esmaeli
    Ophthalmology Section, Department of Plastic Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ophthalmology 109:1188-91. 2002
    ..To compare the frequency of canalicular stenosis as a side effect of weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer...
  71. ncbi request reprint Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis
    Yan M Li
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Cell 6:459-69. 2004
    ..These results provide a plausible mechanism for HER2-mediated breast tumor metastasis and establish a functional link between HER2 and CXCR4 signaling pathways...
  72. ncbi request reprint Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience
    Allen M Chen
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:2303-12. 2004
    ..To determine patterns of local-regional recurrence (LRR) and ipsilateral breast tumor recurrence (IBTR) among patients treated with breast conservation therapy after neoadjuvant chemotherapy...
  73. doi request reprint Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer
    Olivier Graesslin
    FACP, Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 1354, Houston, TX 77030, USA
    J Clin Oncol 28:2032-7. 2010
    ..Selection of an enriched patient population at high risk for brain metastasis will facilitate the design of trials aiming at its prevention...
  74. doi request reprint Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density
    Wei Tse Yang
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Breast Cancer Res Treat 119:305-14. 2010
    ..These results strongly suggest that COX2 inhibition should be investigated for breast cancer prevention despite possible increase in cardiovascular risk...
  75. doi request reprint Breast-conserving surgery in older patients with invasive breast cancer: current patterns of treatment across the United States
    Grace L Smith
    Department of Radiation Oncology, The Section of Health Services Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Am Coll Surg 209:425-433.e2. 2009
    ..But earlier studies report low BCS use rates of 12% to 43% nationally, especially in older patients. We sought to determine current patterns and predictors of BCS use...
  76. pmc Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity
    Fumiyuki Yamasaki
    Breast Cancer Translational Research Laboratory, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 448, Houston, TX 77030 4009, USA
    Mol Cancer Ther 6:2168-77. 2007
    ....
  77. doi request reprint Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger
    Yesim Eralp
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
    J Cancer Res Clin Oncol 135:141-8. 2009
    ..The aim of this study is to evaluate the impact of body mass index (BMI) and various prognostic factors on pathologic response and survival in young patients with localized breast cancer...
  78. ncbi request reprint Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma
    Jianzhou Wang
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 94:3107-14. 2002
    ..In this study, the authors investigated the roles of tumor nuclear grade, mitotic activity, and biomarker expression profiles in predicting the pathologic response of breast tumors to preoperative chemotherapy...
  79. doi request reprint 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer
    Ugo De Giorgi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Nucl Med 51:1213-8. 2010
    ..Our objective was to compare the predictive significance of (18)F-FDG PET/CT findings and circulating tumor cell (CTC) count in patients with bone metastases from breast cancer treated with standard systemic therapy...
  80. doi request reprint Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis
    Fabrice Andre
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:2636-43. 2008
    ..The aim of the present study was to assess the efficacy of adjuvant docetaxel and anthracycline therapy according to ER expression in two randomized clinical trials...
  81. ncbi request reprint Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer
    Nuhad K Ibrahim
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Cancer Invest 20:29-37. 2002
    ..The aim of this study was to determine the MTD of vinorelbine and docetaxel given in combination with G-CSF...
  82. pmc Genomic index of sensitivity to endocrine therapy for breast cancer
    W Fraser Symmans
    Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 28:4111-9. 2010
    ..We hypothesize that measurement of gene expression related to estrogen receptor α (ER; gene name ESR1) within a breast cancer sample represents intrinsic tumoral sensitivity to adjuvant endocrine therapy...
  83. ncbi request reprint Multifocal breast cancer in women < or =35 years old
    Jennifer K Litton
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1445-50. 2007
    ..The relation that multifocality at diagnosis had to survival in women < 35 years of age was evaluated...
  84. ncbi request reprint Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 20:1800-8. 2002
    ..To evaluate the safety and efficacy of weekly docetaxel plus trastuzumab in women with HER-2-overexpressing metastatic breast cancer. Efficacy was correlated with serum HER-2 extracellular domain (ECD) levels...
  85. ncbi request reprint Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials
    Banu Arun
    Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:4943-8. 2007
    ..The optimum method to retrieve adequate samples and the most accepted method by study participants is not known...
  86. ncbi request reprint Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer
    Ana Maria Gonzalez-Angulo
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Clin Breast Cancer 8:516-21. 2008
    ....
  87. doi request reprint Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 26:4679-83. 2008
    ....
  88. pmc Use of intravenous bisphosphonates in older women with breast cancer
    Sharon H Giordano
    Department of Breast Medical Oncology, The University of Texas, Houston, Texas 77030, USA
    Oncologist 13:494-502. 2008
    ..i.v. bisphosphonates reduce skeletal events in women with bone metastases from breast cancer, but little is known about the prevalence and duration of bisphosphonate use...
  89. doi request reprint Molecular predictors of response to trastuzumab and lapatinib in breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Nat Rev Clin Oncol 7:98-107. 2010
    ..In the future, it will be important to characterize mechanisms of resistance in metastatic tumors to determine which novel targeted therapy will be most appropriate for individual patients...
  90. pmc Limits of observational data in determining outcomes from cancer therapy
    Sharon H Giordano
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 112:2456-66. 2008
    ..Observational data are used increasingly to assess the effectiveness of therapies. However, selection biases are likely to have an impact on results and threaten the validity of these studies...
  91. doi request reprint Accuracy of the BRCAPRO model among women with bilateral breast cancer
    Kaylene J Ready
    University of Texas M D Anderson Cancer Center, Department of Breast Medical Oncology, Unit 1354, P O Box 301439, Houston, TX 77230 1439, USA
    Cancer 115:725-30. 2009
    ..The objectives of this study were to determine the accuracy of the BRCAPRO model among women with bilateral breast cancer and to determine whether their mutation status was dependent on their age at first diagnosis...
  92. ncbi request reprint Fast three-dimensional dual echo dixon technique improves fat suppression in breast MRI
    Huong Le-Petross
    Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Magn Reson Imaging 31:889-94. 2010
    ....
  93. ncbi request reprint Gemcitabine in combination with vinorelbine for treatment of advanced breast cancer
    Gabriel N Hortobagyi
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Clin Breast Cancer 3:34-8. 2002
    ..Further studies of the gemcitabine/ vinorelbine combination regimen are warranted..
  94. ncbi request reprint Relationship between epidemiologic risk factors and breast cancer recurrence
    Abenaa M Brewster
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 25:4438-44. 2007
    ..We evaluated the effect of epidemiologic breast cancer risk factors on recurrence in women with early-stage disease...
  95. ncbi request reprint Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 20:17-23. 2002
    ..To define clinical and pathologic predictors of local-regional recurrence (LRR) for patients treated with neoadjuvant chemotherapy and mastectomy without radiation...
  96. ncbi request reprint Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver
    Luis H Camacho
    Phase I Program, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:2190-6. 2007
    ..Systemic paclitaxel is safe and has demonstrated good antitumor activity against breast carcinoma. The objective of this prospective study was to determine the safety and antitumor activity of hepatic intra-arterial paclitaxel therapy...
  97. ncbi request reprint African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy
    Wendy A Woodward
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:2662-8. 2006
    ..African-American (AA) race has been associated with a worse outcome in breast cancer. It is unclear whether this is due to biological factors, socioeconomic factors, or both...
  98. ncbi request reprint The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, Breast Medical Oncology, Surgical Oncology, and Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:8398-402. 2005
    ....
  99. ncbi request reprint Adjuvant systemic therapy for male breast carcinoma
    Sharon H Giordano
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:2359-64. 2005
    ..In the current study, the authors describe the M. D. Anderson experience with adjuvant systemic therapy in male breast carcinoma patients...
  100. ncbi request reprint Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, Unit 424, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 23:7098-104. 2005
    ..To identify clinicopathological factors predictive of distant metastasis in patients who had a pathologic complete response (pCR) after neoadjuvant chemotherapy (NC)...
  101. ncbi request reprint Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:1150-60. 2003
    ..Over the past decade, it has become increasingly more common to deliver chemotherapy first, but this has raised new questions within all disciplines of cancer management...

Research Grants3

  1. UTMDACC SPORE in Breast Cancer
    Gabriel Hortobagyi; Fiscal Year: 2007
    ..Thus, each project's leadership has complementary strengths and areas of expertise that will allow us to work together in the translation of new findings to clinical therapies and screening procedures. ..
  2. UTMDACC SPORE in Breast Cancer
    Gabriel Hortobagyi; Fiscal Year: 2007
    ..Thus, each project's leadership has complementary strengths and areas of expertise that will allow us to work together in the translation of new findings to clinical therapies and screening procedures. ..